Pipeline
Bringing Hope to Life through our NMDA Platform
We focus on serious, life-threatening conditions with major unmet medical needs. Our growing pipeline is powered by our proprietary, dual-targeted mechanism of action, which safely modulates the NMDA and 5HT2A receptors.
As we unlock our discoveries about the role of NMDA receptors throughout the human body, we leverage that research to bring hope to people with:
- Depression
- Suicidality
- Chronic Pain
- PTSD
Therapeutic Areas by Population Size in United States

PSYCHIATRY
BIPOLAR DEPRESSION & SUICIDAL IDEATION
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Severe Bipolar Depression with Recently Suicidal Patients post stabilization
NRX-100™ / NRX-101™
Treatment of Suicidal Treatment-Resistant Bipolar Depression
NRX-101™
Expanded Access / Safety Study
NRX-101™
CHRONIC PAIN WITH DEPRESSION
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Treatment of Chronic Pain
NRX-101™
Depression in Patients with Chronic Pain
NRX-101™
POST TRAUMATIC STRESS DISORDER (PTSD)
Indication
Preclinical
Phase 1
Phase 2
Phase 3
PTSD in patients with Depression & Suicidality
NRX-101™
Sources:
- National Institute of Mental Health, https://www.nimh.nih.gov/health/statistics/bipolar-disorder
- US Dept of Veteran Affairs, https://www.ptsd.va.gov/understand/common/common_adults.asp
- Centers for Disease Control and Prevention, https://www.cdc.gov/mmwr/volumes/72/wr/mm7215a1.htm
Expanded Access Policy on RTT: NRX-101 is not currently available outside of clinical trials.
Follow Us
Keep up with the latest news and updates about NRx through social media.